I. Mandjes

发表

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment

R. Bernards, C. Caldas, Mariette Schrier, 2017 .

Chromosome 11 Putative Tumor Suppressor Regions , Is Limited to Loss of Heterozygosity in Wilms ' Tumors , Studied for Six Updated

C. Heyting, P. Devilee, A. Westerveld, 2006 .

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

S. Linn, H. van Tinteren, R. Rietbroek, 2022, Breast Cancer Research and Treatment.

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

S. Linn, H. van Tinteren, R. Rietbroek, 2022, Breast Cancer Research and Treatment.

A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.

S. Rodenhuis, H. Keizer, E. de Vries, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa.

S. Rodenhuis, J. Baars, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

H. Rosing, J. Beijnen, W. W. ten Bokkel Huinink, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Autosomal dominant aniridia linked to the chromosome 11p13 markers catalase and D11S151 in a large Dutch family.

C. Heyting, A. Westerveld, M. Mannens, 1989, Cytogenetics and cell genetics.

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

A. C. Dubbelman, H. Rosing, J. Beijnen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

S. Linn, M. Kok, J. Wesseling, 2018, European journal of cancer.

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

A. Jager, S. Linn, V. Tjan-Heijnen, 2018 .

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

W. M. Smit, W. Hop, S. Linn, 2010, The Netherlands journal of medicine.

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer

H. Sindermann, J. Beijnen, W. W. ten Bokkel Huinink, 1999, British Journal of Cancer.